To date, 73 % ( 11 of 15 ) of patients who underwent the combination therapy regimen demonstrated sufficient recovery to allow explantation and avoid heart transplantation; freedom from recurrent heart failure in surviving patients was 100 % and 89 % at one and four years after explantation, respectively; average ejection fraction was 64 % at 59 months after explantation all patients were NYHA Class I; and no significant adverse effects were reported with clenbuterol therapy.
12.
To date, 73 % ( 11 of 15 ) of patients who underwent the combination therapy regimen demonstrated sufficient recovery to allow explantation and avoid heart transplantation; freedom from recurrent heart failure in surviving patients was 100 % and 89 % at one and four years after explantation, respectively; average ejection fraction was 64 % at 59 months after explantation all patients were NYHA Class I; and no significant adverse effects were reported with clenbuterol therapy.
